PHVS Biotechnology · Rare disease · Pre-revenue · Late-stage biotech · Thesis updated July 17, 2026

A one-pill HAE bet got less risky

Pharvaris has no product revenue yet, so this is a clinical and regulatory story first.
Its whole pipeline centers on deucrictibant, an oral drug meant to block the pathway that causes swelling attacks.
The on-demand IR capsule cleared a major Phase 3 hurdle in December 2025.
The next big test is the FDA New Drug Application planned for the first half of 2026.
The bear case is simple: one molecule, no sales, and more Phase 3 data still ahead.

01 Running thesis

The pill promise

Pharvaris is trying to make treatment for hereditary angioedema, or HAE, easier. HAE is a rare disease that can cause sudden swelling attacks. Many current treatments involve injections. Deucrictibant is designed as an oral pill.

The bull case became stronger after the Phase 3 RAPIDe-3 study reported positive topline data in December 2025. Phase 3 means a large late-stage human trial. The immediate-release, or IR, capsule met its main goal and key secondary goals with statistical significance, according to the company filing.

That shifts the story from pure trial risk to execution risk. Pharvaris plans to submit a New Drug Application, or NDA, to the US Food and Drug Administration in the first half of 2026 for on-demand treatment of HAE attacks.

The bear case has not gone away. The company still depends on one molecule. The extended-release, or XR, prevention version still needs Phase 3 CHAPTER-3 data, expected in the second half of 2026.

Apr 2026▲Pharvaris reported that RAPIDe-3 met its primary and key secondary goals for the IR capsule. The main near-term question moved from trial readout to the planned FDA NDA in the first half of 2026.

Apr 2025→The baseline view framed Pharvaris as a pre-revenue rare disease biotech built around deucrictibant. The key risks were single-molecule dependence, trial execution, and the need for outside funding.

02 Business model

No sales yet

Pharvaris is pre-revenue. It has not recorded product sales in the periods covered by its annual filings, and it does not expect revenue until it can commercialize a first product.

For now, the company spends mainly on research and development for deucrictibant. If approved, the business would likely shift from trial spending to launch spending, including doctors, payers, patient support, and drug supply.

This model can work well in rare disease if a drug is clearly better and patients need it often. It can also break fast if the FDA delays approval, if safety questions appear, or if the prevention version misses its trial.

03 Product portfolio

One molecule, several shots

Growth engine

Deucrictibant IR for on-demand HAE

This immediate-release capsule is meant to treat HAE attacks when they happen. RAPIDe-3 met its main and key secondary goals, and the planned FDA NDA is the next step.

Option

Deucrictibant XR for HAE prevention

This extended-release tablet is meant to prevent HAE attacks before they start. CHAPTER-3 topline Phase 3 data is the key watch item in the second half of 2026.

Option

CREAATE for AAE-C1INH attacks

Pharvaris initiated CREAATE, a global pivotal Phase 3 study, in October 2025. It tests deucrictibant for acquired angioedema tied to C1 inhibitor deficiency.

Option

Other bradykinin-mediated diseases

Deucrictibant blocks the bradykinin B2 receptor, a switch involved in swelling attacks. Future uses depend on clinical proof beyond the current late-stage programs.

04 Business segments

One operating segment

Deucrictibant development operating segment100%growing fast

Commercial revenue0%flat

Pharvaris reports as a single biopharmaceutical operating segment and had no revenue in the covered annual filing periods. The mix shown treats development activity as the whole operating base, with no commercial revenue yet.

05 Risk factors

What could break

First FDA filing risk

High impact · Medium odds

The IR program has positive Phase 3 data, but it still needs a complete FDA review. Pharvaris is preparing its first NDA, so filing quality and regulator questions matter a lot.

We watchFDA acceptance of the IR NDA, review timing, and any complete response letter or major review delay.

CHAPTER-3 prevention miss

High impact · Medium odds

The XR tablet is the prevention version of the drug. A weak Phase 3 CHAPTER-3 readout would narrow the market opportunity and leave the company more dependent on on-demand use.

We watchTopline CHAPTER-3 data expected in the second half of 2026, especially attack-rate reduction and safety.

Single-molecule concentration

High impact · High odds

Nearly the whole company depends on deucrictibant. If the molecule has a safety, efficacy, manufacturing, or regulatory problem, there is no broad pipeline to cushion the hit.

We watchAny safety signal, FDA question, trial hold, or manufacturing issue tied to deucrictibant.

Funding before revenue

Medium impact · Medium odds

Pharvaris has not generated product revenue. Until approval and launch, it must fund trials, filings, and launch preparation with cash on hand and outside capital.

We watchCash runway disclosures, new share offerings, debt terms, and quarterly research and development spending.

Clinical hold memory

Medium impact · Low odds

The company has already experienced FDA clinical holds in 2022. That history does not mean a new hold will happen, but it shows how quickly the timeline can change.

We watchAny FDA safety communication, trial pause, protocol change, or added data request.

06 Quick answers

In one breath

What does Pharvaris make?

Pharvaris is developing deucrictibant, an oral drug for angioedema attacks. It has an IR capsule for treating attacks and an XR tablet for preventing attacks.

Does Pharvaris have revenue?

No product revenue has been recorded in the annual filing periods cited. The company needs approval and commercialization before it can sell its first product.

What is the biggest 2026 catalyst for PHVS?

The first catalyst is the planned FDA NDA submission for the IR capsule in the first half of 2026. The next major one is Phase 3 CHAPTER-3 data for the XR prevention tablet in the second half of 2026.

Why is deucrictibant important?

It could offer injection-like benefit in an oral pill if the full data and FDA review support the profile. That matters because HAE patients often need fast, reliable treatment during swelling attacks.